Vav-iCre transgenic mice have the mouse HS21/45 control regions directing expression of an optimized variant of Cre recombinase (iCre) to hematopoietic cells (and their progenitors), and may be useful for generating conditional mutations in hematopoietic cells.
In Goodwin et al. 2019 Genome Res. 29:494, it was discovered that the transgene integrated into an intron of Commd10 (COMM domain containing 10) on chromosome 18 - creating a Commd10 null allele.
Dimitris Kioussis, MRC Natl Inst for Med Research
Genetic Background | Generation |
---|---|
N16+pN1
|
Allele Type |
---|
Transgenic (Recombinase-expressing, Null/Knockout) |
Starting at:
$255.00 Domestic price for female 4-week |
333.51 Domestic price for breeder pair |
These transgenic mice express Cre recombinase under the control of the mouse vav 1 oncogene (Vav1) promoter. The transgene integrated into an intron of Commd10 (COMM domain containing 10) on chromosome 18. The insertion results in a functional knock-out of Commd10 in homozygous mice.
Mice hemizygous for this Vav-iCre transgene are viable and fertile, with the mouse HS21/45-vav control regions directing expression of an optimized variant of Cre recombinase (iCre) to hematopoietic cells (and their progenitors). Using crosses to a reporter strain, variegated germ line (testis and ovaries), and heart and gut expression is also reported. When bred with mice containing a loxP-flanked sequence of interest, Cre-mediated recombination will result in deletion of the floxed sequence(s) in the offspring. These Vav-iCre transgenic mice may be useful for generating conditional mutations in hematopoietic cells.
Joseph et al. 2013 Cell Stem Cell 13:520 reports that Vav-iCre mice express iCre in hematopoietic cells and endothelial cells, as well as in the testes. For Cre-lox experiments and to avoid/minimize germline deletion of the floxed allele, researchers may consider breeding Vav-iCre females with floxed males. However, female germline expression may also be observed (see below).
If the recombinase activity pattern of this allele is further characterized by the Genetic Resource Science group at The Jackson Laboratory, such findings will be reported on the Mouse Genome Informatics (MGI) Allele Detail entry (Commd10Tg(Vav1-icre)A2Kio). This same information would also be found searching the MGI Recombinase Activity database.
This Vav-iCre strain (Stock No. 008610) allows reliable deletion of specific genes throughout the entire hematopoietic compartment, whereas the hCD2-iCre strain (Stock No. 008520) allows targeting to be focused to T cells and B cells.
The Vav-iCre transgene was designed with the mouse vav 1 oncogene (Vav1) promoter region (containing the 2 proximal upstream DNase-I hypersensitive (HS) sites (HS21)), an optimized variant of Cre recombinase (iCre; improved with mammalian codon usage, removed putative cryptic splce sites, altered stop codon, and reduced CpG content to limit the chances of epigenetic silencing in mammals) and an SV40 polyA signal replacing Vav1 exon 1, and Vav1 intron 1 (containing both proximal HS sites (HS45)). The transgene was microinjected into the pronuclei of fertilized oocytes from (CBA/Ca x C57BL/10)F1 mice. Founder mice (founder line ".A2") were established and used to generate mutant mice. The resulting Vav-iCre transgenic mice were subsequently bred to wildtype C57BL/6 mice for more than 16 generations prior to arrival at The Jackson Laboratory Repository. Upon arrival, the Vav-iCre transgenic mice were bred to C57BL/6J inbred mice (Stock No. 000664) to establish the colony. As of 2015, SNP testing mice from several pedigree lines showed all 5 markers determining C57BL/6 substrain to be C57BL/6J allele-type.
In 2018, it was discovered that the transgene integrated into an intron of Commd10 (COMM domain containing 10) on chromosome 18 - creating a null allele.
Expressed Gene | cre, cre recombinase, bacteriophage P1 |
---|---|
Site of Expression | Cre recombinase is expressed in lymph nodes, thymus, spleen, Peyer's patches, intestinal cryptopatches, ovaries and testes. |
Allele Name | transgene insertion A2, Dimitris Kioussis |
---|---|
Allele Type | Transgenic (Recombinase-expressing, Null/Knockout) |
Allele Synonym(s) | Tg(Vav1-cre)1Kio; Tg(Vav1-cre)A2Kio; Tg(Vav1-icre)A2Kio; Vav1 (HS21/5)-iCre; Vav1-Cre; VavCre; Vav-cre; VavCredeBoer; Vav-iCre |
Gene Symbol and Name | Commd10, COMM domain containing 10 |
Gene Synonym(s) | |
Promoter | Vav1, vav 1 oncogene, mouse, laboratory |
Expressed Gene | cre, cre recombinase, bacteriophage P1 |
Site of Expression | Cre recombinase is expressed in lymph nodes, thymus, spleen, Peyer's patches, intestinal cryptopatches, ovaries and testes. |
Strain of Origin | (CBA/Ca x C57BL/10)F2 |
Chromosome | 18 |
Molecular Note | This transgene expresses Cre recombinase under the control of a vav promoter. This promoter was shown to be active in lymph nodes, thymus, spleen, Peyer's patches, intestinal cryptopatches, ovaries and testes. Line A2 inserted into the gene at 47022629-47022630 (Build GRCm38/mm10). The insetion results in a functional knock-out in homozygous mice. |
Mutations Made By | Dimitris Kioussis, MRC Natl Inst for Med Research |
When maintaining a live colony, hemizygous mice may be bred to wildtype (noncarrier) siblings or to C57BL/6J. The donating investigator reports that homozygous mice are not viable.
Joseph et al. 2013 Cell Stem Cell 13:520 reports that Vav-iCre mice express iCre in hematopoietic cells and endothelial cells, as well as in the testes. For Cre-lox experiments and to avoid/minimize germline deletion of the floxed allele, researchers may consider breeding Vav-iCre females with floxed males. However, female germline expression may also be observed (see the Mouse Genome Informatics (MGI) Allele Detail entry: Commd10Tg(Vav1-icre)A2Kio).
When using the Vav-iCre mouse strain in a publication, please cite the originating article(s) and include JAX stock #008610 in your Materials and Methods section.
Service/Product | Description | Price |
---|---|---|
Hemizygous or non-carrier for Tg(Vav1-cre)A2Kio |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.